Arcus set Nov. 4, 2026, to report results; analysts expect $7.58 million in sales and a $0.89-per-share loss. These are estimates, not reported results, so the story does not change Arcus's outlook.
A date and outside estimates do not show how Arcus's business performed. The expected loss per share is a forecast, not an actual result, and the story gives no comparison with earlier results.
Follow Arcus Biosciences, Inc. (RCUS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCUS